Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition. Int J Dermatol Venereol. 2020;3(1):14–26.

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590.

Article  PubMed  PubMed Central  Google Scholar 

Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–7.

Article  PubMed  Google Scholar 

Chen K, Wang G, Jin H, Xu J, Zhu X, Zheng M, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8(28):46381–9.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong AW, Read C. Pathophysiology, Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–60.

Article  CAS  PubMed  Google Scholar 

Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CE, Bundy C. Measurement, classification and evaluation of sleep disturbance in psoriasis: a systematic review. PLoS One. 2016;11(6): e0157843.

Article  PubMed  PubMed Central  Google Scholar 

Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases–focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55–61.

Article  PubMed  Google Scholar 

Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26(5):448–59.

Article  PubMed  Google Scholar 

Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis. Indian J Dermatol. 2017;62(2):113–22.

Article  PubMed  PubMed Central  Google Scholar 

Augustin M, Sommer R, Kirsten N, Danckworth A, Radtke MA, Reich K, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358–65.

Article  CAS  PubMed  Google Scholar 

Yang Z, Yao X, Wang M, Li H, Li R. Updates in psoriasis diagnosis and treatment status in China: results from the National Psoriasis Center Registry. Chin Med J (Engl). 2023;136(23):2874–6.

PubMed  Google Scholar 

Blome C, Gosau R, Radtke MA, Reich K, Rustenbach SJ, Spehr C, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308(2):69–78.

Article  PubMed  Google Scholar 

Gorelick J, Shrom D, Sikand K, Renda L, Burge R, Dworkin C, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther (Heidelb). 2019;9(4):785–97.

Article  PubMed  Google Scholar 

Honma M, Cai Z, Burge R, Zhu B, Yotsukura S, Torisu-Itakura H. Relationship between rapid skin clearance and quality of life benefit: post hoc analysis of japanese patients with moderate-to-severe psoriasis treated with ixekizumab (UNCOVER-J). Dermatol Ther (Heidelb). 2020;10(6):1397–404.

Article  PubMed  Google Scholar 

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, et al. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138–49.

Article  CAS  PubMed  Google Scholar 

Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-54.e9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.

Article  CAS  PubMed  Google Scholar 

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.

Article  CAS  PubMed  Google Scholar 

Li X, Zheng J, Pan W-L, Zheng M, Lu Y, Li F-Q, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venereol. 2022;5(04):181–90.

Article  Google Scholar 

van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477–82.

Article  PubMed  Google Scholar 

Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28(4):282–7.

Article  CAS  PubMed  Google Scholar 

Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686–92.

Article  CAS  PubMed  Google Scholar 

Papp KA, Gerdes S, Leonardi CL, Elmaraghy H, See K, McKean-Matthews M, et al. Sustained high efficacy and favorable safety over five years in patients with burdensome psoriasis (UNCOVER-1/UNCOVER-2). J Drugs Dermatol. 2021;20(8):880–7.

Article  PubMed  Google Scholar 

Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, et al. Characterization of patients with psoriasis in challenging-to-treat body areas in the corrona psoriasis registry. Dermatology. 2021;237(1):46–55.

Article  PubMed  Google Scholar 

Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3.

Article  PubMed  PubMed Central  Google Scholar 

Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirisap N, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med (Lausanne). 2023;10:1185523.

Article  PubMed  Google Scholar 

Bagel J DK, Burgy J, Herman E, McDonald MF, Vadhariya A, Malatestinic WN, See K, Zhu B, Merola JF. Early improvement in nail and scalp psoriasis from a prospective observational study of patients with psoriasis in special areas (PSoSA) initiating ixekizumab: results from the first interim analysis. 2024.

Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76(6):675–705.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wasel N, Thaçi D, French LE, Conrad C, Dutronc Y, Gallo G, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663–70.

Article  PubMed  Google Scholar 

Li Y, Lv C, Dang L, Lin B, Tao J, Zhang C, et al. Effectiveness of ixekizumab in chinese patients with moderate-severe plaque psoriasis with special area involvement: subanalysis of a prospective, multicenter. Observational real-world study. Dermatol Ther (Heidelb). 2024;14(4):907–18.

Article  PubMed  Google Scholar 

Nicolescu AC, Ionescu MA, Constantin MM, Ancuta I, Ionescu S, Niculet E, et al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness. Life (Basel). 2022;12(12):2050.

PubMed  Google Scholar 

Committee on Psoriasis CSoD. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023;56(7):573–625.

Wang S, Zhu J, Wang P, Dong J, Li Y, Shi D, et al. Nail psoriasis in China: a prospective multicentre study. J Eur Acad Dermatol Venereol. 2024;38(3):549–56.

Article  CAS  PubMed  Google Scholar 

Hebert AA, Bobonich MA, Rodriguez Capriles C, Gallo G, Li L, Somani N, et al. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis. Pediatr Dermatol. 2022;39(1):55–60.

Article  PubMed  Google Scholar